Next-Generation Nanobody Targeting TCR and IL3RA for Precision Cancer Therapy

VHH-P584 is a humanized nanobody designed to target both the alpha-beta T Cell Receptor Complex (TCR) and interleukin 3 receptor subunit alpha (IL3RA), two clinically relevant molecules implicated in cancer. Currently in the Biological Testing phase, VHH-P584 has been developed as a trivalent single-domain antibody fusion construct. By simultaneously engaging TCR and IL3RA, VHH-P584 represents an innovative therapeutic approach for cancer with the potential to modulate distinct signaling pathways and enhance treatment efficacy. This program aims to address unmet clinical needs in cancer care through a novel mode of action leveraging nanobody technology.

Licensing Opportunity

VHH-P584 is available for out-licensing to partners interested in advancing next-generation oncology therapeutics. Collaboration inquiries from biotech and pharma companies are welcomed to unlock its full clinical and commercial potential.

Development Phase

Modality

VHH-P584 is a trivalent immunoglobulin single variable domain antibody, incorporating one anti-TCR VHH and two anti-CD123 (IL3RA) VHHs connected via flexible 35GS linkers and featuring a C-terminal alanine. This structure allows for specific, multi-epitope engagement with target receptors, while the nanobody format provides advantages such as small molecular size for enhanced tumor penetration, high stability, and solubility. The modular nature and single-domain configuration of VHH-P584 facilitate access to challenging tumor environments, making it especially suitable for disrupting tumoral signaling in cancer. Its extended modularity also supports future engineering adaptability, crucial for evolving oncology needs.

Target

TCR and IL3RA are pivotal molecular targets in cancer immunotherapy. TCR is a membrane-bound receptor complex found primarily on T lymphocytes and plays a crucial role in antigen recognition and cellular immune responses. IL3RA is a cell surface receptor subunit predominantly expressed on certain hematologic malignancies and is associated with aberrant cell signaling in cancer. Both TCR and IL3RA offer distinctive target biology: TCR is critical for adaptive immunity modulation, while IL3RA is overexpressed on tumor cells, including leukemias. Targeting TCR and IL3RA enables VHH-P584 to address various malignancies by altering immune cell function and directly targeting tumor cells. The combined focus on TCR and IL3RA enhances the strategic value of VHH-P584 in developing innovative therapies addressing cancer’s complexity.

Mechanism of Action

VHH-P584 is designed to modulate oncogenic pathways through dual targeting of TCR and IL3RA, leveraging distinct but complementary mechanisms. By binding to TCR, VHH-P584 may modulate T cell activity and signal transduction, potentially overcoming immune evasion mechanisms in the tumor microenvironment. Simultaneously, targeting IL3RA enables direct interaction with tumor cells expressing this receptor, resulting in signal disruption linked to cell survival and proliferation. The trivalent configuration enhances avidity and target specificity. Moreover, the nanobody platform supports further functionalization, such as conjugation for ADCs or generating multispecific constructs, thus expanding therapeutic applications in oncology and beyond.

Cancer

Cancer remains one of the most significant global health challenges, accounting for millions of new cases and deaths annually. It encompasses a diverse group of diseases characterized by uncontrolled cell proliferation and the ability to invade distant tissues. Standard therapeutic approaches include surgery, chemotherapy, radiation therapy, immunotherapy, and targeted agents. Although therapeutic advancements have improved patient outcomes in several malignancies, significant unmet needs remain, including drug resistance, off-target effects, and limited efficacy in certain subtypes. The heterogeneity and adaptability of cancer necessitate novel therapeutics able to selectively target tumor-specific pathways and the immune microenvironment. VHH-P584, by simultaneously engaging TCR and IL3RA, introduces a dual-action approach with the potential to overcome current therapeutic limitations, improve specificity, and address the critical challenge of achieving durable responses in refractory and relapsed cancers.